The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.
The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.
View the complete ESMO Congress 2020 programme online
Tuesday, 15 September 2020
ESMO Colloquium: Controversies in endometrial cancer: Update on ESMO clinical practice guidelines (CPG) and future treatment direction
13:00-14:30
This educational activity is provided by ESMO and funded by Eisai Europe Ltd.
View the ESMO colloquium details
Learning Objectives
- Access new data on Endometrial Cancer
- Learn about how treatment selection can rely on Molecular Biology features
- Reposition the combined modality approach for RT/CT
- Navigate within the various types of Endometrial cancers
- Review the state of the Art and the updates in ESMO Guidelines and Consensus conference
Tuesday, 22 September 2020
ESMO Colloquium: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
13:00-14:30
This educational activity is provided by ESMO and supported by Lilly.
View the ESMO colloquium details
Learning Objectives
- Understand the role of RET and its molecular alteration in cancer biology
- Review the present results of RET targeting in Thyroid and Non-Small-Cell Lung carcinomas
- Access the latest ESMO recommendations on RET in Breast cancer
- Consider RET as a possible target for an agnostic treatment approach
Wednesday, 23 September 2020
ESMO Colloquium: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
13:00-14:30
This educational activity is provided by ESMO and supported by Lilly.
View the ESMO colloquium details
Learning Objectives
- Review the recent outcomes of EGFR mutant metastatic NSCLC treated with 3rd generation EGFR TKI
- Decide whether or not single agent EGFR TKI is still standard of care
- Access recent combination data of EGFR TKI with either chemotherapy or anti-angiogenic or even Immune-checkpoint inhibitors